Note: EPS may not be comparable

SenesTech, Inc. (NASDAQ: SNES) reported FY17 EPS Loss of $1.12.

2017 Annual Financial Results

• Revenues from product sales during 2017 were $52,000, compared to less than $1,000 of revenue from product sales during 2016. During 2016, the company received $132,000 in NIH grants, and $186,000 in licensing fees under our former license agreement with Neogen.
• Operating expenses during 2017 were $12.3 million, compared to $10.8 million during 2016. Operating expenses during 2017 included non-cash equity compensation of $3.7 million. The increase in operating expense was attributable largely to expansion of product commercialization activities. The Company anticipates that operating cash utilization will continue at or below $750,000 per month.
• Net loss during 2017 was $12.3 million or $1.12 per share, compared to $11.0 million, or $1.71 per share, during 2016.
• Adjusted EBITDA, which is a non-GAAP measure of operating performance, was $(8.2) million during 2017, compared to $(6.0) million during 2016.
• Cash, cash equivalents and highly liquid investments at the end of the year were $7.1 million.

For earnings history and earnings-related data on SenesTech, Inc. (SNES) click here.